IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a report released on Wednesday. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Down 9.3 %

IRIX stock opened at $0.86 on Wednesday. The stock has a market capitalization of $14.47 million, a PE ratio of -1.29 and a beta of 0.94. The company has a fifty day moving average of $1.30 and a 200-day moving average of $1.55. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. IRIDEX has a one year low of $0.78 and a one year high of $3.65.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Thursday, March 27th. The medical equipment provider reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $12.70 million during the quarter, compared to the consensus estimate of $12.80 million.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.